Lucus Advisors LLC decreased its position in shares of Amedisys Inc. (NASDAQ:AMED) by 37.4% during the second quarter, Holdings Channel reports. The institutional investor owned 6,921 shares of the company’s stock after selling 4,137 shares during the period. Lucus Advisors LLC’s holdings in Amedisys were worth $349,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of AMED. Acrospire Investment Management LLC bought a new position in shares of Amedisys during the first quarter worth approximately $108,000. M&T Bank Corp bought a new position in shares of Amedisys during the first quarter worth approximately $367,000. Capstone Asset Management Co. raised its position in shares of Amedisys by 2.6% in the second quarter. Capstone Asset Management Co. now owns 8,929 shares of the company’s stock worth $451,000 after buying an additional 230 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Amedisys by 56.7% in the second quarter. BNP Paribas Arbitrage SA now owns 10,965 shares of the company’s stock worth $554,000 after buying an additional 3,966 shares in the last quarter. Finally, Algert Global LLC raised its position in shares of Amedisys by 32.1% in the first quarter. Algert Global LLC now owns 12,975 shares of the company’s stock worth $627,000 after buying an additional 3,155 shares in the last quarter. 91.45% of the stock is currently owned by institutional investors and hedge funds.
Shares of Amedisys Inc. (NASDAQ:AMED) traded up 0.27% during mid-day trading on Friday, hitting $47.44. The company’s stock had a trading volume of 352,605 shares. The company has a 50-day moving average of $48.27 and a 200 day moving average of $49.66. The company has a market cap of $1.59 billion, a price-to-earnings ratio of 41.50 and a beta of 1.05. Amedisys Inc. has a 1-year low of $31.16 and a 1-year high of $55.16.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, August 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.42. The business had revenue of $360 million for the quarter, compared to the consensus estimate of $353.07 million. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. Amedisys’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. On average, analysts expect that Amedisys Inc. will post $1.69 EPS for the current year.
AMED has been the topic of a number of analyst reports. Wells Fargo & Co. reissued a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Jefferies Group reissued a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $57.00 target price for the company in a research note on Tuesday, July 5th. Stephens started coverage on Amedisys in a research note on Thursday, June 16th. They set an “equal weight” rating and a $55.00 target price for the company. Finally, Mizuho downgraded Amedisys from a “buy” rating to a “neutral” rating and decreased their target price for the company from $57.00 to $55.00 in a research note on Wednesday, August 3rd. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Amedisys presently has an average rating of “Hold” and an average target price of $51.75.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc. (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.